Review ArticleIllusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings
Section snippets
Testing for Achieved Renal Denervation
The belief that renal denervation has been achieved in clinical trials of catheter-based renal denervation is almost invariably based on hope and trust, rather than testing. This contrasts with the studies of surgical renal denervation in experimental hypertension, where good experimental design necessitates that the effectiveness of denervation is always confirmed, typically by documenting 90–95% reduction in the kidney content of norepinephrine.
Among clinical studies of renal denervation,
Renal Denervation “Armageddon”: The Symplicity HTN-3 Trial
A challenge to the percutaneous renal denervation treatment of resistant hypertension came with the 9 January 2014 press release concerning the Simplicity HTN-3 trial in drug-resistant hypertension, the pivotal study for US Food and Drug Administration licensure, and in the subsequent New England Journal of Medicine publication on 29 March,23 indicating that the primary efficacy endpoint had not been reached in the trial.
A lot was expected of the Symplicity HTN-3 study. Five times larger than
Development of a More Generally Accessible Method for Testing Efferent Sympathetic Nerve Ablation?
There is a pressing need to incorporate valid testing for renal sympathetic denervation into all clinical trials of the procedure. Growing acceptance has emerged for this important principle, but some of the planned testing for denervation, such as using measurements of heart rate variability, are fanciful. In truth, it is difficult to know how to proceed, as the only validated test for renal denervation, measurement of renal norepinephrine spillover,4, 6 has very limited availability and could
Afferent Renal Nerves and Their Ablation
Sensory nerves running from the kidneys to the central nervous system contribute to activation of the sympathetic nervous system in patients with drug-resistant hypertension, through their projection to the hypothalamus.29 Ablation of these nerves during the renal denervation procedure contributes to BP lowering by causing central inhibition of central sympathetic outflow.30 The nociceptive receptors within the kidney, which are responding to a renal injury signal,29 can be targeted with
The Future of Renal Denervation in Treating Severe Hypertension
The Symplicity HTN-3 trial has inflicted a “flesh wound” on the renal denervation field, but this is not fatal; the trial is now seen to have failed in its neuroscience execution, not effectively and consistently achieving renal denervation.24 In the pause that this trial created world-wide, it is now time to reflect on what future science is needed (Table 3). Failure to test for renal denervation, as an intrinsic component of all trials but one, represents the Achilles heel of the field. It is
References (30)
- et al.
Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension
J Am Coll Cardiol
(2011) - et al.
Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study
Lancet
(2009) - et al.
Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study
Lancet
(2014) - et al.
Anatomical distribution of human renal sympathetic nerves: pathological study
J Am Coll Cardiol
(2014) - et al.
Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring
Hypertension
(2011) Prevalence of resistant hypertension in the United States, 2003-2008
Hypertension
(2011)Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomized controlled trial
Lancet
(2010)- et al.
Measurement of total and organ-specific norepinephrine kinetics in humans
Am J Physiol
(1984) - et al.
The assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover
Hypertension
(1988) - et al.
Dissociation between muscle and skin sympathetic nerve activity in essential hypertension, obesity, and congestive heart failure
Hypertension
(1998)
Differing patterns of sympathoexcitation in normal weight and obesity-related hypertension
Hypertension
Translational medicine: the antihypertensive effect of renal denervation
Am J Physiol (Regul Integr Comp Physiol)
Sympathetic neural activation in nondiabetic metabolic syndrome and its further augmentation by hypertension
Hypertension
Neural mechanisms in human obesity-related hypertension
J Hypertens
Neural control of renal function
Physiol Rev
Cited by (102)
Controversies in Hypertension IV: Renal Denervation
2023, American Journal of MedicineNeuromodulation therapy for atrial fibrillation
2023, Heart RhythmRenal Artery Denervation in Resistant Hypertension: The Good, The Bad and The Future
2020, Heart Lung and CirculationRenal Denervation Update From the International Sympathetic Nervous System Summit: JACC State-of-the-Art Review
2019, Journal of the American College of CardiologyRationale and Design of Sympathetic Mapping/Ablation of Renal Nerves Trial (SMART) for the Treatment of Hypertension: a Prospective, Multicenter, Single-Blind, Randomized and Sham Procedure-Controlled Study
2023, Journal of Cardiovascular Translational Research
The author is a Senior Director of the Baker IDI Heart and Diabetes Institute Melbourne, and Conjoint Professor of Medicine Monash University, Melbourne. His primary funding is in the form of a Senior Principal Research Fellowship from the Australian National Health and Medical Research Council [ID586601]. He discloses research funding and receipt of consultancy fees, travel expenses, and honoraria from Medtronic, which funded the research from which some of the presented results are drawn, but the author holds no shares in the company or patent rights for renal denervation. In the preparation of this article no financial or other support was provided by Medtronic.